Related Experiment Video

Updated: Jul 18, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Gefitinib efficacy associated with multiple expression of HER family in non-small cell lung cancer

Makoto Nishio1, Fumiko Taguchi, Fumiyoshi Ohyanagi

  • 1Thoracic Oncology Center, Cancer Institute Hospital, Ariake 3-10-6, Koto-ku, Tokyo 135-8550, Japan. mnishio@jfcr.or.jp

Anticancer Research
|November 11, 2006
PubMed
Abstract

Insights

Multiple human epidermal growth factor receptor (HER) family expressions correlate with better clinical response to gefitinib in non-small cell lung cancer (NSCLC) patients. Triple HER expression indicates improved treatment outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacogenomics

Background:

  • Gefitinib is a targeted therapy for non-small cell lung cancer (NSCLC).
  • The human epidermal growth factor receptor (HER) family plays a role in cancer development and treatment response.
  • Understanding HER family expression patterns can optimize gefitinib therapy.

Purpose of the Study:

  • To investigate the association between HER family expression and clinical outcomes in NSCLC patients treated with gefitinib.
  • To determine if specific HER family co-expression patterns predict gefitinib response.

Main Methods:

  • Analysis of HER family (EGFR, HER2, HER3, HER4) expression in tumor tissues from 31 NSCLC patients using immunohistochemistry.
  • Correlation of HER family expression levels with objective response rate (RR) and time to progression (TTP).

Main Results:

  • High expression rates for EGFR (68%), HER2 (77%), and HER3 (55%) were observed.
  • 45% of patients exhibited triple expression of EGFR, HER2, and HER3/HER4.
  • Patients with triple HER expression showed significantly higher RR (50% vs. 11%) and longer TTP (4.29 vs. 1.2 months) compared to others.

Conclusions:

  • Co-expression of multiple HER family members may predict a favorable clinical response to gefitinib.
  • HER family expression status could be a biomarker for gefitinib efficacy in NSCLC.
  • Further research into EGFR mutation status alongside HER family expression is warranted.

More Related Videos

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...